lundi 24 août 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· July 28, 2026

Stocks Mixed on Earnings Results and Weakness in Chipmakers

View original at nasdaq.com
Stocks Mixed on Earnings Results and Weakness in Chipmakers The S&P 500 Index ($SPX) (SPY) today is up +0.05%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.738%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -1.12%…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Claimed to have struck facilities linked to Saudi Aramco in the Red Sea port towns of Jizan and Yanbu on Saturday

    60% confidence
  • Q2 earnings may increase by +23%, close to Q1's blowout earnings of +30%, which was more than double the +12% analysts had expected

    60% confidence
  • Forecasting Q3 net sales of $1.95 billion to $2.05 billion, weaker than the consensus of $2.11 billion

    60% confidence
  • Raised the possibility of intensified action against Iran

    60% confidence
  • Reported Q2 net sales of $10.40 billion, above the consensus of $10.03 billion

    60% confidence
  • Raising its full-year comparable EPS forecast to up +9% to +10% from a previous view of +8% to +9%

    60% confidence
  • Boosting full-year revenue forecast to $17.28 billion to $17.48 billion from a previous forecast of $17.15 billion to $17.35 billion, stronger than consensus of $17.28 billion

    60% confidence
  • Cutting full-year adjusted EBITDA estimate to $850 million to $925 million from a previous forecast of $940 million to $1.02 billion, below consensus of $970.3 million

    60% confidence
  • Downgraded RXO to sell from hold with a price target of $19

    60% confidence
  • Upgraded Intuitive Surgical to buy from hold with a price target of $500

    60% confidence
  • Forecasting Q3 core sales of $4.9 billion to $5.0 billion, the midpoint below the consensus of $5.0 billion

    60% confidence
  • Reported adjusted EPS of $3.70, better than the consensus of $3.51, and raised full-year adjusted EPS forecast to $11.80 to $12.20

    60% confidence

Cité dans ces articles de Via News

Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Notre lecture des données ›
Signaux que nous suivons
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Tendances que nous surveillons ›
Là où les sources divergent
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
Nous signalons les conflits ouvertement ›
Vérifié récemment
Vérifié avec la source d'origine
4,978
faits reliés à leur source — et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,978 faits vérifiés avec la source5,251 documents sources archivés
Interrogez ces données → isubstrate.com